QUEST DIAGNOSTICS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DGX$259.67+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $420 | $549 |
| Accounts receivable, net of allowance for credit losses of $25 and $29 as of December 31, 2025 and 2024, respectively | 1,408 | 1,304 |
| Inventories | 189 | 188 |
| Prepaid expenses and other current assets | 361 | 351 |
| Total current assets | 2,378 | 2,392 |
| Property, plant and equipment, net | 2,203 | 2,113 |
| Operating lease right-of-use assets | 657 | 651 |
| Goodwill | 8,945 | 8,856 |
| Intangible assets, net | 1,636 | 1,763 |
| Investments in equity method investees | 136 | 123 |
| Other assets | 270 | 255 |
| Total assets | $16,225 | $16,153 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,600 | $1,394 |
| Current portion of long-term debt | 504 | 602 |
| Current portion of long-term operating lease liabilities | 174 | 173 |
| Total current liabilities | 2,278 | 2,169 |
| Long-term debt | 5,167 | 5,615 |
| Long-term operating lease liabilities | 537 | 535 |
| Other liabilities | 957 | 938 |
| Commitments and contingencies | ||
| Redeemable noncontrolling interest | 80 | 83 |
| Stockholders’ equity: | ||
| Quest Diagnostics stockholders’ equity: | ||
| Common stock, par value $0.01 per share; 600 shares authorized as of both December 31, 2025 and 2024; 162 shares issued as of both December 31, 2025 and 2024 | 2 | 2 |
| Additional paid-in capital | 2,381 | 2,361 |
| Retained earnings | 9,994 | 9,360 |
| Accumulated other comprehensive loss | (27) | (88) |
| Treasury stock, at cost; 52 shares and 51 shares as of December 31, 2025 and 2024, respectively | (5,180) | (4,857) |
| Total Quest Diagnostics stockholders’ equity | 7,170 | 6,778 |
| Noncontrolling interests | 36 | 35 |
| Total stockholders’ equity | 7,206 | 6,813 |
| Total liabilities and stockholders’ equity | $16,225 | $16,153 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.